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ABSTRACT
Objective:  We conducted a pooled analysis of published studies to compare the performance 
of human papillomavirus (HPV) testing and cytology in detecting residual or recurrent 
diseases after treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2/3).
Methods:  Source articles presenting data on posttreatment HPV testing were identified 
from the National Library of Medicine (PubMed) database. We included 5,319 cases from 33 
articles published between 1996 and 2013.
Results:  The pooled sensitivity of high-risk HPV testing (0.92; 95% confidence interval [CI], 
0.90 to 0.94) for detecting posttreatment CIN 2 or worse (CIN 2+) was much higher than that 
of cytology (0.76; 95% CI, 0.71 to 0.80). Co-testing of HPV testing and cytology maximized 
the sensitivity (0.93; 95% CI, 0.87 to 0.96), while HPV genotyping (detection of the same 
genotype between pre- and posttreatments) did not improve the sensitivity (0.89; 95% CI, 
0.82 to 0.94) compared with high-risk HPV testing alone. The specificity of high-risk HPV 
testing (0.83; 95% CI, 0.82 to 0.84) was similar to that of cytology (0.85; 95% CI, 0.84 to 0.87) 
and HPV genotyping (0.83; 95% CI, 0.81 to 0.85), while co-testing had reduced specificity 
(0.76; 95% CI, 0.75 to 0.78). For women with positive surgical margins, high-risk HPV 
testing provided remarkable risk discrimination between test-positives and test-negatives 
(absolute risk of residual CIN 2+ 74.4% [95% CI, 64.0 to 82.6] vs. 0.8% [95% CI, 0.15 to 4.6]; 
p<0.001).
Conclusion:  Our findings recommend the addition of high-risk HPV testing, either alone 
or in conjunction with cytology, to posttreatment surveillance strategies. HPV testing can 
identify populations at greatest risk of posttreatment CIN 2+ lesions, especially among 
women with positive section margins.
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INTRODUCTION
Cytology-based cervical cancer screening programs have greatly reduced the large burden 
of invasive cervical cancer worldwide by detecting many premalignant lesions (cervical 
intraepithelial neoplasia grade 2 [CIN 2] or grade 3 [CIN 3]) before these lesions progressed 
to invasive diseases. Many women diagnosed with premalignant diseases are treated by local 
therapy including laser ablation, the loop electrosurgical excision procedure (LEEP) and 
cone biopsies, and 5% to 15% of these women are diagnosed with CIN 2 or CIN 3 or cervical 
cancer (CIN 2+) again after treatment [1-3]. Women who have been treated for CIN 2 or CIN 
3 have 2.8 times higher risk of invasive cervical cancer for the subsequent 20 years compared 
with women who have not been treated [4]. Therefore, it is of great importance to efficiently 
identify women at increased or decreased risk of developing residual or recurrent CIN 2+ after 
treatment.
Japan and most European countries perform cytology-based follow-up after treatment of 
high-grade CIN [5-7]. By contrast, in the United States, co-testing of human papillomavirus 
(HPV) testing and cytology has been incorporated into the posttreatment surveillance 
strategy as well as the primary screening program [8]. The current guideline of American 
Society for Colposcopy and Cervical Pathology (ASCCP) recommends co-testing of HPV 
testing and cytology at 12 and 24 months after treatment [8]. However, this recommendation 
is not based on evidence from randomized controlled trials (RCTs). Although recent large-
scale RCTs have demonstrated that high-risk HPV testing, alone or in combination with 
cytology, can detect CIN 2+ more sensitively than cytology alone in the setting of primary 
screening [9], no RCT has been conducted for HPV testing during posttreatment follow-up.
In the present study, we conducted a systematic review of 33 published studies that presented 
data on HPV-based testing methods for the detection of posttreatment residual or recurrent 
CIN 2+ [10-42]. This pooled analysis included a large number of women (n=5,322) and 
compared the test performance (sensitivity, specificity, positive predictive value [PPV], and 
negative predictive value [NPV]) of various HPV-based test methods (hybrid capture 2 [HC2] 
test [Qiagen, Hilden, Germany], polymerase chain reaction [PCR]-based oncogenic HPV 
assays, oncogenic HPV persistence [defined as detection of the same oncogenic HPV type(s) 
between pre- and posttreatments]) with that of cytology in detecting posttreatment CIN 2+. 
We also addressed the influence of surgical margin status on the performance of HPV testing 
for predicting residual disease.
MATERIALS AND METHODS
To assess the performance of HPV-based testing methods for detecting residual or recurrent 
CIN 2+ in women treated for CIN 2 or CIN 3, we conducted a pooled analysis of published 
data. Identification of relevant studies was conducted independently by two reviewers 
(MO and KM) using a multi-step process. Relevant articles presenting the performance of 
posttreatment HPV testing were identified from National Library of Medicine (PubMed) 
database. We used the following search terms: CIN, treatment, HPV, posttreatment, 
conization or LEEP or laser, and recurrence, persistence or residual. Reference lists of 
systematic reviews and meta-analyses identified from this computer-aided search were used 
to search for additional relevant articles that might have been missed in the initial search. 
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The literature search identified 1,143 citations, of which 1,002 were excluded by their titles 
(Fig. 1). After reviewing the abstracts of the remaining 141 citations, a further 43 citations 
were considered not relevant and 98 citations underwent full text review by two reviewers. 
Studies were included if the following criteria were fulfilled: (1) women were treated for CIN 
2+ using surgical procedures, laser ablation or cryotherapy, (2) the women were subsequently 
tested for HPV-DNA within 12 months after treatment, and (3) the final eventual outcome 
(the presence or absence of biopsy-proven residual or recurrent CIN 2+) was documented. 
Studies in which the presented data were insufficient to calculate sensitivity and specificity of 
HPV testing in detecting posttreatment CIN 2+ were excluded. We chose CIN 2+ as a clinically 
important outcome rather than CIN 3+ because: (1) the histological distinction between 
CIN 2 and CIN 3 is poorly reproducible and (2) CIN 2 is used as a threshold for treatment in 
current guidelines [6-8]. In studies in which cytologic testing were also performed, we used 
a threshold of atypical squamous cells of undetermined significance (ASC-US) to define a 
positive result because ASC-US is a threshold for further examination in current guidelines [5-
8]. Studies with small sample size (<20 women) or high rates of loss to follow-up (>30%), and 
studies reporting follow-up data of pregnant or HIV-positive women were excluded. Studies 
concerning women immunized with prophylactic HPV vaccines were also excluded. Overall, 
the review was limited to a total of 33 studies that reported the performance of posttreatment 
HPV testing between 1996 and 2013, using HPV-based testing methods to identify at least 13 
oncogenic strains of HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68 [10-42]. When 
data or data subsets from an identical study had been published in more than one article, 
only the publication with the largest sample size was included. However, data from different 
studies conducted by the same study group were included.
Initial Pubmed search
1,143 Articles
98 Articles
33 Articles
Included in analyses
1,045 Excluded by screening title and abstract
65 Excluded on the basis of full text review
   56 No accuracy data for recurrent or residual CIN2+
     4 Short duration of follow-up
     3 Missing data of posttreatment HPV testing
     1 Small sample size
     1 Double reporting (subset analysis)
Fig. 1.  Literature search. Initial search through PubMed identified 1,143 articles for our systematic review. 
After reviews of titles, abstracts and full texts, 33 eligible articles were included in our analysis [10-42]. CIN 2, 
cervical intraepithelial neoplasia grade 2; HPV, human papillomavirus.
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For statistical analyses, two reviewers (MO and KM) extracted the following data from full 
texts of eligible studies: study characteristics (authors, year of publication, and country, study 
design), patient characteristics (sample size, mean or median age and range, initial treatment 
and surgical margin status), findings from HPV testing, cytology and cervical biopsies, type of 
HPV test (HC2, PCR-based assays and genotyping), timing of HPV assay and cytologic testing 
after treatment and mean or median length of follow-up and range. Data of test results were 
extracted into 2×2 tables of residual or recurrent CIN 2+ versus test results of HPV assay alone, 
cytology alone, and co-testing, which was used to calculate pooled sensitivity, specificity, and 
PPV and NPV. Also, studies were categorized according to type of HPV assays and surgical cut 
margin status. We reviewed characteristics of individual studies and assessed heterogeneity 
to determine whether pooling was appropriate. When appropriate, pooled sensitivity and 
specificity were calculated by a bivariate normal model. In 2×2 table analyses, statistical tests 
were two-sided and the p-values obtained in all tests were considered significant at <0.05. We 
used the JMP ver. 10.0J (SAS Institute, Cary, NC, USA) for statistical analysis.
RESULTS
1. Test performance of cytology and HPV testing for detecting posttreatment 
CIN 2+
In the pooled analysis, a total of 5,319 women from 33 prospective and retrospective studies 
were evaluated for the performance of HPV testing for the detection of residual or recurrent 
CIN 2+, and 446 women (8.4%) were histologically diagnosed with CIN 2+ again during 
follow-up (Appendix 1) [10-42]. Of the 5,319 women included in this pooled analysis, 1,667 
women from 12 studies were genotyped twice (pre-treatment and posttreatment) [10-21], 
which allowed us to assess the ability of detection of oncogenic HPV persistence to predict 
residual or recurrent CIN 2+. Also, information on surgical margin status was obtained from 
2,153 women reported in 14 studies [14,15,22-33]. The pooled sensitivity and specificity 
of cytology and the combination of HPV DNA test and cytology (co-testing) for detecting 
posttreatment CIN 2+ was evaluated in 4,232 women from 22 studies [13,15,16,18-22,25-
29,34-42] and in 2,409 women from 11 studies [13,16,19,25,26,35-40], respectively.
The pooled sensitivity of HPV testing for detecting posttreatment CIN 2+ was much higher 
than that of ASC-US+ threshold cytology ([0.92; 95% CI, 0.90 to 0.94] vs. [0.76; 95% CI, 0.71 
to 0.80]). The sensitivity did not vary between HPV detection methods: 0.94 (95% CI, 0.91 
to 0.96) for HC2 testing, 0.92 (95% CI, 0.87 to 0.95) for PCR-based assays and 0.89 (95% CI, 
0.82 to 0.94) for oncogenic HPV persistence (HPV genotyping). The high sensitivity of HPV 
testing yielded the highest NPV (0.99; 95% CI, 0.99 to 1.00). The pooled sensitivity of co-
testing (0.93; 95% CI, 0.87 to 0.96) was slightly higher than that of HPV testing alone.
The pooled specificity of HPV testing for the detection of residual or recurrent CIN 2+ was 
similar to that of ASC-US+ threshold cytology ([0.83; 95% CI, 0.82 to 0.84] vs. [0.85; 95% 
CI, 0.84 to 0.87]). The specificity did not differ according to HPV detection method: 0.84 
(95% CI, 0.83 to 0.85) for the HC2 test, 0.81 (95% CI, 0.79 to 0.83) for PCR-based methods, 
and 0.83 (95% CI, 0.81 to 0.85) for oncogenic HPV persistence. The pooled specificity of co-
testing (0.76; 95% CI, 0.75 to 0.78) was the lowest of all test methods. The percentage of 
referral to colposcopy was the highest in co-testing (28.0%), followed by cytology (19.1%) 
and HPV testing (15.9%) (Table 1).
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Surgical cut margin status did not affect the test performance (sensitivity and specificity) 
of carcinogenic HPV testing. In women with positive surgical margins, the sensitivity and 
specificity of HPV testing for predicting residual CIN 2+ were very high (sensitivity: 0.98, 
95% CI, 0.91 to 0.99; specificity: 0.85, 95% CI, 0.78 to 0.90). Similarly, the sensitivity and 
specificity were considerably high even in women with negative margins (sensitivity: 0.91, 
95% CI, 0.79 to 0.97; specificity: 0.80, 95% CI, 0.76 to 0.83).
2. Risk stratification provided by carcinogenic HPV testing, cytology, and 
surgical margin positivity
We investigated to what extent carcinogenic HPV testing, cytology and surgical margin 
histology could discriminate the risk of posttreatment CIN 2+ among women treated for 
cervical precancerous lesions (Fig. 2). The absolute risk of residual or recurrent CIN 2+ 
lesions was 32.7% (95% CI, 30.2 to 35.4) among HPV-positive women, but only 0.9% (95% 
CI, 0.6 to 1.2) among HPV-negative women (odds ratio [OR], 56.0; 95% CI, 44.9 to 70.0; 
Table 1.  Test performance of HPV testing and cytology for detection of posttreatment CIN 2 or worse
Testing methods No. of women 
included in analysis
No. of test-positive 
women (colposcopy 
referral rate, %)
Detection of recurrent or residual CIN 2 or worse
Sensitivity (95% CI) Specificity (95% CI) PPV (95% CI) NPV (95% CI)
High-risk HPV test* 5,322 1,119 (21.0) 0.91 (0.88–0.94) 0.83 (0.82–0.84) 0.28 (0.26–0.31) 0.99 (0.99–1.00)
HPV genotyping† 1,667 399 (23.9) 0.89 (0.82–0.94) 0.83 (0.81–0.85) 0.28 (0.24–0.33) 0.99 (0.98–0.99)
Cytology‡ 3,656 813 (22.2) 0.74 (0.68–0.79) 0.85 (0.83–0.86) 0.25 (0.22–0.28) 0.98 (0.97–0.98)
Co-testing§ 2,287 645 (28.2) 0.92 (0.87–0.96) 0.76 (0.74–0.78) 0.20 (0.17–0.23) 0.99 (0.99–1.00)
CIN 2, cervical intraepithelial neoplasia grade 2; HPV, human papillomavirus; NPV, negative predictive value; PPV, positive predictive value. 
*High-risk HPV tests, all HPV DNA detection assays detecting at least 13 carcinogenic HPV genotypes. †HPV genotyping, detection of HPV persistence between 
pre- and posttreatments. ‡Cytology, atypical squamous cells of undetermined significance threshold. §Co-testing, combination test of both high-risk HPV test 
and cytology.
Fig. 2.  Risk stratification of posttreatment cervical intraepithelial neoplasia grade 2+ (CIN 2+) provided by 
carcinogenic human papillomavirus (HPV) testing, cytology, and surgical margin histology. In each test method 
of high-risk HPV testing, cytology (atypical squamous cells of undetermined significance+) or surgical margin 
histology, the absolute risks of having recurrent or residual CIN 2+ lesions (■) and 95% confidence intervals (error 
bars) were calculated for women testing positive or negative for each test. HPV testing provided the greatest risk 
stratification between test-positive and -negative women.
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p<0.001). Also, this risk was 29.6% (95% CI, 26.5 to 32.8) among women with ASC-US+ 
cytology, but decreased to 2.2% (95% CI, 1.8 to 2.8) among those with normal cytology (OR, 
18.3; 95% CI, 14.7 to 22.6; p<0.001). In addition, we confirmed that a pooled recurrence 
rate was significantly higher in women with positive margins (29.7%; 95% CI, 25.4 to 34.4) 
than in those with negative margins (6.1%; 95% CI, 5.1 to 7.3) (OR, 6.45; 95% CI, 5.0 to 8.4; 
p<0.001). Although each of HPV testing, cytology and surgical margin histology was useful 
for posttreatment risk assessment, HPV testing provided the greatest risk discrimination 
between test-positive and -negative women (Fig. 2). This finding supports the clinical utility 
of incorporating HPV testing into posttreatment surveillance strategies.
The addition of carcinogenic HPV testing to cytology provided additional, more precise 
risk stratification among women treated for CIN 2+ (Fig. 3). The absolute risk of recurrent 
or residual CIN 2+ lesions was highest among both-positive women (29.9%; 95% CI, 25.3 
to 35.0), followed by HPV-positive and cytology-negative women (13.3%; 95% CI, 9.4 to 
18.5). This risk of posttreatment CIN 2+ was still high among HPV-negative but cytology-
positive women (5.8%; 95% CI, 3.0 to 11.1), suggesting that this population would still need 
colposcopy referral. For women with both-negative results, the absolute risk of posttreatment 
CIN 2+ was found to be extremely low (0.9%; 95% CI, 0.4 to 2.0).
Interestingly, HPV testing for women with positive margins provided remarkable risk 
discrimination for having residual CIN 2+ (Fig. 3): women with positive HPV results had a 
residual CIN 2+ risk of 67.5% (95% CI, 52.3 to 80.2), while HPV-negative women had a risk of 
only 1.3% (95% CI, 0.4 to 12.5) (OR, 289.1; 95% CI, 63.0 to 1,325.1; p<0.001). This residual 
CIN 2+ risk in margin-positive but HPV-negative women was similar to that in women with 
both-negative results (0.9%; 95% CI, 0.4 to 2.2).
Fig. 3.  Further risk stratification of posttreatment cervical intraepithelial neoplasia grade 2+ (CIN 2+) provided 
by the addition of carcinogenic human papillomavirus (HPV) testing to cytology and surgical margin histology. 
Carcinogenic HPV testing provided additional risk stratification for posttreatment CIN 2+ lesions according to 
cytology results (atypical squamous cells of undetermined significance+) or surgical margin status. The absolute 
risks of having recurrent or residual CIN 2+ lesions and 95% confidence intervals (error bars) were calculated for 
HPV-positive (■) and -negative women (■) in each category group.
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DISCUSSION
In this pooled analysis, high-risk HPV testing had a higher sensitivity than cytology for 
predicting posttreatment CIN2+, as well as comparable specificity; this was in keeping with 
previously conducted meta-analyses [1-3]. The increased sensitivity of HPV testing over 
cytology suggests that HPV testing should be incorporated into posttreatment surveillance 
strategies. The diagnostic accuracy of HPV testing for detecting CIN 2+ in posttreatment 
settings has been shown to be similar to that in primary screening settings [9]. The greatest 
sensitivity for detecting posttreatment disease was reached by co-testing with the HPV test 
and cytology. The sensitivity of co-testing for detecting residual or recurrent CIN 2+ was 
higher than that of separate individual tests. Because the risk for CIN 2+ is much higher in 
women treated for CIN 2 or CIN 3 than in screening populations, maximizing sensitivity may 
be more important than emphasizing specificity in posttreatment surveillance of potentially 
lethal diseases. These observations support the current ASCCP guideline recommending co-
testing of HPV testing and cytology at 12 and 24 months after treatment of women with CIN 2 
or CIN 3 [8]. However, the difference in sensitivity between HPV testing alone and co-testing 
was very small, suggesting that testing for carcinogenic HPV without adjunctive cytology may 
be sufficiently sensitive for monitoring of women treated for CIN 2 or CIN 3. In the present 
study, HPV testing alone resulted in fewer referrals for colposcopy than did co-testing (referral 
rate, 15.9% vs. 28.0%). Taking into consideration a cost of excessive referral to colposcopy, 
HPV testing without adjunctive cytology may achieve the maximum benefit.
In the present study, the test performance for predicting residual or recurrent disease did not 
differ according to type of HPV-based test method. However, detection of oncogenic HPV 
persistence (defined as detection of the same HPV type between pre- and posttreatment) 
had a slightly reduced sensitivity compared with the HC2 test and PCR-based oncogenic 
HPV testing. Although all CIN 2+ lesions detected after treatment are a priori considered 
to be residual or recurrent lesions, this reduced sensitivity may have reflected a proportion 
of incident lesions arising from acquisition of a new HPV after successful treatment. 
Testing for carcinogenic HPVs, rather than detection of HPV persistence by expensive HPV 
genotyping, is recommended for posttreatment surveillance to identify not only women with 
residual disease, but also women with high-risk HPV infections who are at increased risk for 
developing incidental lesions.
Although surgical cut margin positivity was significantly associated with elevated risk of 
residual disease, performance of HPV testing was unaffected by surgical margin status. 
However, for women with positive section margins, HPV testing may be useful for identifying 
populations at increased or decreased risk of residual disease: HPV-positive women had a 
residual CIN 2+ risk of 67.5%, while HPV-negative women had a risk of only 1.3%. Even in 
women having positive cut margins, negative HPV results conferred as low a risk as that in 
women with both-negative results. Thus, HPV testing may likely provide greater reassurance 
for HPV-negative women, thereby permitting safe extension of follow-up intervals.
The present study had several limitations. Our findings from this pooled analysis were 
limited by the quality of available published studies, publication bias, selection bias, and 
differences between included studies (for instance, differences in treatment methods, time 
from treatment to first HPV test, types of HPV detection assays, follow-up periods, number of 
repeated cytology examinations, types of cytology [conventional vs. liquid-based cytology], 
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histological assessment of section margin, diagnostic accuracy of treatment failure, etc.). 
In addition, the heterogeneity of the included studies may be greater than that of previous 
pooled analyses because of the relatively wide inclusion criteria of this present review. 
Therefore, our pooled analysis was still insufficient to establish detailed follow-up algorithms 
for women treated for CIN 2/3. However, despite these limitations, we attempted a pooled 
analysis because of the lack of RCTs and the relatively small size of previous meta-analyses 
evaluating the posttreatment performance of HPV testing. A recent meta-analysis of eight 
well-designed studies indicated that high-risk HPV testing has a higher sensitivity compared 
with cytology in detecting posttreatment CIN 2+, and a similar specificity [3]. However, the 
number of women included in this meta-analysis was relatively small (n=1,512), and >50% 
of the data was obtained from only two studies. Another meta-analysis demonstrated similar 
results, but focused only on the posttreatment performance of the HC2 test, a commercialized 
HPV test used commonly worldwide to detect one or more of the representative 13 oncogenic 
HPV genotypes [2]. In addition, the sample size of that meta-analysis was also relatively small 
(n=1,032 from five studies). Based on the largest pooled data analysis (n=5,322) to date from 
33 published studies [10-42], the present study confirmed the usefulness of HPV testing in 
detecting residual or recurrent diseases after treatment for CIN 2/3.
Our search found few studies with long-term follow-up data on women treated for CIN 2 or 
CIN 3. Therefore, our pooled analysis could not evaluate the subsequent risk of cervical cancer 
and precancerous lesions after 2-year posttreatment surveillance. However, a longitudinal 
cohort study of Dutch women treated for CIN 2 or CIN 3 demonstrated that the absolute 5- 
and 10-year risk of CIN 2+ in women with negative co-testing results at 6 and 24 months after 
treatment is very low (1.0% and 3.6%, respectively) [43], this is similar to that of women with 
normal cytology in primary cervical cancer screening [9].
Cost-utility analysis would be needed for incorporation of high-risk HPV assays into 
posttreatment follow-up of women treated for CIN 2 or CIN 3. Japan and most European 
countries perform cytology-based follow-up after treatment of CIN 2 or CIN 3 [5-7]. In the 
Netherlands and UK, the current guideline recommends repeated cytology at 6, 12, and 
24 months after treatment; following three consecutive negative smears, women return to 
population-based routine screening [6,7]. In Japan, cytology (3,900 Japanese Yen [JPY]) 
is more expensive than high-risk HPV testing (3,600 JPY). Therefore, employing HPV 
testing alone (3,600 JPY) or co-testing with cytology (7,500 JPY) as a single test to decide 
whether Japanese women treated for CIN 2 or CIN 3 can return to routine screening would 
substantially reduce the cost of posttreatment surveillance in comparison with repeated 
cytology (11,700 JPY).
In conclusion, the present study, based on the largest pooled data analysis to date from 
33 published studies [10-42], revealed that HPV testing was more sensitive than cytology 
in detecting posttreatment CIN 2+, and had an equal specificity compared with cytology. 
Additionally, HPV genotyping to detect persistent infection by the same HPV type did not 
improve sensitivity and specificity compared with HC2 tests and other PCR-based assays. 
Women with positive surgical margins may benefit mostly from high-risk HPV testing because 
of very high PPV and NPV. The present pooled analysis confirmed and expanded the results 
from previous studies and meta-analyses [1-3]. On the basis of our findings and the data from 
other published meta-analyses, the addition of HPV testing to posttreatment surveillance 
strategies is recommended for better protection against cervical cancer and precancerous 
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lesions. However, large-scale RCTs are warranted to establish detailed evidence-based follow-
up algorithms for women treated for CIN 2 or CIN 3.
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Appendix 1.  Studies included in the pooled analysis of the performance of posttreatment human papillomavirus testing*
Author (Reference No.) Journal Publication 
Year
Country HPV test Time from 
treatment to first 
HPV test (mo) 
N Follow-up (mo) 
(mean or median 
[range])
Treatment Cytology
Elfgren K et al. [13] Am J Obstet 
Gynecol
1996 Sweden PCR (GP5+6+) 6 22 16-27 Cone LBC
Chua KL et al. [22] Gynecol Oncol 1997 Sweden PCR (GP5+6+) <12 48 1-98 Cone conventional
Distefano AL et al. 
[14]
Infect Dis Obstet 
Gynecol
1998 Argentina PCR (GP5+6+) 6-12 36 6-12 LEEP NA
Bollen LJ et al. [10] Gynecol Oncol 1999 Netherlands PCR (CPI/IIG) <24 43 13-206 Cone/LEEP/
Cryo/laser
LBC
Nagai Y et al. [25] Gynecol Oncol 2000 Japan PCR (L1C1/
L1C2)
6-12 58 31.8 (12-73) LEEP NA
Jain S et al. [23] Gynecol Oncol 2001 Taiwan HC2 6 wk 79 6-8 wk LEEP LBC
Nobbenhuis MA et al. 
[35]
Br J Cancer 2001 Netherlands PCR (GP5+6+) 6 184 24 (3-76) LEEP conventional
Bodner K et al. [24] Anticancer Res 2002 Austria HC2 3 37 24 Cone LBC
Bekkers RL et al. [15] Int J Cancer 2002 Netherlands PCR (SPF10) 6 90 24-47 LEEP LBC+conventional
Bar-Am A et al. [41] Gynecol Oncol 2003 Israel HC2 6 67 63 (50-72) LEEP NA
Almog B et al. [12] Gynecol Oncol 2003 Israel HC1 6 96 47 (36-60) Cone NA
Zielinski GD et al. [36] Gynecol Oncol 2003 Netherlands HC2 3 108 29 (2-65) Cone/LEEP NA
Cecchini S et al. [37] Tumori 2004 Italy PCR (pU1/U2) 6 84 22.8 (11-40) LEEP NA
Sarian LO et al. [38] Gynecol Oncol 2004 Brazil HC2 6 88 17 LEEP conventional
Nagai N et al. [25] Int J Mol Med 2004 Japan PCR (L1C1/
L1C2)
<12 161 78 (48-118) LEEP LBC
Hernádii Z et al. [11] Eur J Obstet 
Gynecol Reprod Biol
2005 Hungary HC2 5 61 25 (3-62) LEEP NA
Verguts J et al. [26] BJOG 2006 Belgium HC2 3-6 72 24 LEEP LBC
Alonso I et al. [42] Gynecol Oncol 2006 Spain HC2 6 203 20±13 LEEP conventional
Kreimer AR et al. [16] Cancer Epidemiol 
Biomarkers Prev
2006 USA HC2 6 610 24 LEEP LBC
Fallani MG et al. [33] Eur J Gynaecol 
Oncol
2007 Italy PCR (Nanogen) 3-6 66 24 Cone NA
Bae JH et al. [27] Int J Gynecol Cancer 2007 Korea HC2 6-12 114 30.7±13.5 LEEP NA
Kitchener HC et al. 
[39]
BJOG 2008 UK HC2 6 917 24 NA LBC
Brismar S et al. [17] Am J Obstet 
Gynecol
2009 Sweden PCR (Linear 
Array)
12 84 34 (4-115) LEEP conventional
Ribaldone R et al. [30] Arch Gynecol Obstet 2010 Italy PCR (INNO-
LiPA)
4 78 35.7 Cone NA
Smart OC et al. [40] Aust N Z J Obstet 
Gynaecol
2010 New 
Zealand
HC2 <18 100 9 (3-18) Cone/LEEP/
laser
LBC
Gallwas J et al. [28] Eur J Gynaecol 
Oncol
2010 Germany HC2 <12 107 21.4 (2-76) Cone conventional
Leguevaque P et al. 
[31]
Eur J Surg Oncol 2010 France PCR (GP5+6+) 6 352 73 LEEP NA
Kang WD et al. [18] Int J Gynecol Cancer 2010 Korea HC2,PCR (HDC) 3-24 672 >24 LEEP NA
Heymans J et al. [19] Int J Cancer 2011 Belgium PCR (E6/E7) 6 63 24 Cone LBC
Valasoulis G et al. [20] Gynecol Oncol 2011 Greece PCR (MY09/11) 6 188 14 LEEP LBC
Torne A et al. [29] BJOG 2012 Spain HC2 6 109 24 LEEP LBC
Ryu A et al. [32] J Gynecol Oncol 2012 Korea HC2 3 183 25.3±13.3 LEEP LBC
Söderlund-Strand A et 
al. [21]
J Med Virol 2013 Sweden PCR (GP5+6+) 6 142 36 LEEP conventional
HC, hybrid capture; LBC, liquid based cytology; LEEP, loop electrosurgical excision procedure; NA, not available; PCR, polymerase chain reaction.
*These studies were included in the pooled analysis to compare the performance of HPV testing and cytology in detecting residual or recurrent diseases after 
treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN 2 or CIN 3).
